Thymosin alpha-1 is a prescription medicine in more than 35 countries, and its biggest trial came back flat. Among 1,106 adults with sepsis, about 23 in every 100 died on the peptide, against 24 in every 100 on a dummy injection (Trial). TB-500 sits at the other end of the evidence. A 2026 sports medicine review says the human data in bone and joint medicine are still missing (Review). Both are injected drugs. Neither is approved in the United States, and neither is safe to try on yourself.
What These Peptides Are
Thymosin alpha-1 is a chain of 28 amino acids, first found in the thymus (Review). The thymus is the small gland that trains your immune cells, and this peptide is one of the signals it sends. Chemists make a synthetic copy called thymalfasin, sold as Zadaxin. That copy is a registered medicine in more than 35 countries, mainly for long-running hepatitis B and C (Review).
Thymosin beta-4 is a different molecule with a confusingly similar name. It is a protein of 43 amino acids. Its job is moving cells around and repairing tissue, not sending immune signals (Analysis).
TB-500 is where the confusion starts. It is a market label, not a medicine, and sellers usually describe it as thymosin beta-4. A doping lab took a TB-500 product apart and found a seven-amino-acid fragment copied from one stretch of the full protein (Analysis). So TB-500 and thymosin beta-4 are not the same thing. Most sales copy blurs that line.
Neither one is a supplement. A vitamin tops up what your food may lack. These are drugs, at a dose set by whoever filled the vial.
Thymosin Alpha-1 in Sepsis
Sepsis is what happens when an infection tips the whole body into organ failure. It is one of the biggest killers in intensive care. Nothing reliably fixes it, so a drug that steadies the immune system sounds appealing.
The first serious test was the ETASS trial in 2013. It signed up 367 patients at six Chinese teaching hospitals, and 361 were followed to day 28 (Trial). Half got thymosin alpha-1 under the skin, and half got nothing extra. By day 28, 26 in every 100 had died in the peptide group, against 35 in every 100 in the other group.
That gap looks large, and the authors still reported it as a hint. It was small enough that chance could explain it, so they wrote only that the drug “may be effective” (Trial). One of their two ways of crunching the numbers just cleared the usual bar. The main comparison did not.
Two design flaws weakened it further. Patients were kept in the dark, but their doctors were not, because no matching dummy injection existed. The trial was also built to spot a much bigger drop in deaths than it found.
Twelve years later the answer arrived. The TESTS trial enrolled 1,106 adults with sepsis across 22 hospitals (Trial). A coin flip decided who got the peptide and who got a dummy injection, and nobody involved knew which. The treatment group got 1.6 mg twice a day for a week. By day 28, about 23 in every 100 had died on thymosin alpha-1, against about 24 in every 100 on the dummy. The authors found no clear sign that the drug lowers deaths in sepsis.
The peptide was at least easy to tolerate. Roughly two thirds of each group had a side effect of some kind, and the two groups looked much the same (Trial).
A 2025 pooled analysis tells the same story from another angle. Researchers combined 11 trials covering 1,927 patients (Meta-analysis). Overall, deaths by day 28 looked lower on the peptide. Then they sorted the trials by quality. The five stronger trials held 1,568 of those patients, and among them the survival benefit vanished (Meta-analysis). It came almost entirely from six smaller, weaker trials holding 359 patients between them. Sorting by hospital count did the same. Trials run at several hospitals showed no survival benefit. The authors add that the pooled trials never reached the size needed to settle the question.
That pattern repeats across medicine. Small trials run at a single hospital tend to flatter treatments. The tie-breaker is a large trial spread across many hospitals, where nobody knows who is getting what. An earlier pooled analysis in 2015 looked strongly positive across 12 trials and 1,480 patients (Meta-analysis). Its own authors warned that the studies were small and poor quality. They called for exactly the trial that later came back flat.
Why the COVID Data Is Weaker
Most people who have heard of this peptide heard about it in 2020. A paper in a major infectious disease journal reported that severe COVID-19 patients given it died less often (Study). Around 11 in every 100 died on the drug, against 30 in every 100 without it. The gap is striking, and the way the study was built cannot support it.
It was a look-back at old records. Researchers reviewed 76 severe cases at two hospitals in Wuhan. No coin flip decided who got the peptide. Doctors did, one patient at a time, for reasons the records never captured.
That leaves a hole nobody can fill in later. Perhaps the sickest patients were passed over. Perhaps the drug went to the ward with more staff. Either would produce these numbers even if the drug did nothing.
Pooling the COVID-19 studies does not rescue the case, because the pool is made of the same material. One 2023 review gathered 9 studies and 5,417 people, and 7 of the 9 were look-backs rather than trials (Meta-analysis). Deaths came out about the same either way. A second 2023 review, also covering 9 studies, found no clear effect and advised against using the drug in adults in hospital (Meta-analysis). A third pooled 8 studies and did report fewer deaths, while its own authors wrote that proper trials are still needed (Meta-analysis).
Three teams read one body of evidence and reached three different verdicts. The studies also disagreed sharply with each other, and two of the reviews saw hints of benefit in the sickest patients.
What the drug is licensed for abroad is narrower and duller. Regulators have cleared thymalfasin for hepatitis B, and as a booster for vaccine response in people with weakened immune systems (Review). That review comes from someone at the maker, so treat it as a list of approvals. Being registered in a market is a legal fact about that market, not a score for how well a drug works.
TB-500’s Missing Human Trials
In August 2026, a search of the main international trial registry for TB-500 found one record (Registry). That record describes itself, in its own summary, as a fictional example. Searches pairing thymosin with tendon, ligament or sports injury bring back nothing.
Thymosin beta-4 itself has been tested in people, though not for sports injuries. The healing trials that finished used it on the surface of the body: gels for pressure sores and leg ulcers. None used the short fragment sold as TB-500.
The fullest human data come from eye drops. RGN-259 is a thymosin beta-4 drop that reached two late-stage trials, known as phase 3.
The dry eye trial, ARISE-3, was properly built: 700 people, dummy drops, and nobody knowing who got what (Trial). It had two main goals at day 15, how the eye looked and how it felt. The company reported that it missed both. The one improvement it did report was on grittiness, a lesser goal further down the list (Report).
The second trial treated neurotrophic keratopathy, a rare condition where the cornea stops healing itself. It was designed for 46 people and stopped early with 18 (Trial). The registry lists it as terminated (Registry). Of those 18, 6 of 10 on the drop had healed by day 29, against 1 of 8 on the dummy drops. The direction is encouraging. With only 18 people, the gap was still small enough that chance could explain it.
So the strongest human evidence for this family is an eye drop, used on the surface of the eye, in two trials that underdelivered. None of that tells you what happens when a fragment of a related protein is injected near a shoulder.
The healing claims rest on animals and cells instead. The newest example landed in July 2026. Thirty-two rats had an Achilles tendon cut and repaired, and the ones given TB-500 ended up with stronger tendons and healthier tissue (Study). Adding BPC-157 on top changed nothing. The authors call the work a first look and ask for more. A 2026 sports medicine review puts it plainly. These peptides help tissue repair in animals, and the human data in bone and joint medicine are missing (Review). A second 2026 review adds that solid human safety data are scarce, and that social media pumps up the placebo effect around peptides (Review).
What Is Actually in the Vial
Suppose the animal data are enough for you. You still do not know what is in the syringe.
Belgian researchers bought 27 peptide products from three suspected illegal internet pharmacies, all sold as research chemicals (Analysis). Three were thymosin products, and two of those labels said TB-500. All three vials held the full-length protein of 43 amino acids instead, a different molecule from the one on the label.
The wider batch was worse. Some products were as little as 5% pure. Two vials of one product held 4.4 mg and 61.6 mg of powder, a fourteenfold gap. Six samples carried arsenic above the limit for an injectable, several times over, and all of it was the more toxic form.
A French team reached a similar conclusion in 2023 (Analysis). They took apart three products bought online. What was sold as TB500 and TB1000 did not reliably match its description. A related healing product from the same corner of the market was mostly sheep tissue extract and blood proteins.
To be fair, sometimes the vial really does hold the short fragment. That is what the doping lab found in the sample it tested (Analysis). So the honest summary is not that these products are always fake. It is that you cannot know which molecule you have, or how much of it.
This is what “for research use only” is doing on the label. It is not a quality grade. It shifts the legal responsibility onto the buyer, and it runs right through the research peptide gray market. No pharmacist checked that vial, and nobody confirmed the molecule.
Legal Status and Doping Rules
This part moves fast, so treat it as a snapshot of early August 2026.
In the United States, neither peptide is an approved drug. Pharmacies that mix drugs to order may only work from an approved list, and neither peptide is on it. In April 2026 the FDA removed 12 peptides from a holding category attached to that list, after their nominations were withdrawn (Analysis). Removal is not approval, and it made none of them eligible for compounding.
On 23 July 2026, an FDA advisory committee recommended adding TB-500 to the compounding list by 8 votes to 6, with one member not voting (Report). The FDA’s own reviewers had argued against it. They reported that they could not find a single human clinical study of TB-500. The committee voted the same way for BPC-157 and KPV.
The vote changed nothing yet, because such recommendations are not binding. As of early August 2026 these peptides still cannot be lawfully compounded, and the FDA can still act against pharmacies that make them (Analysis). Changing that needs formal rulemaking or an act of Congress, and the rulemaking runs into 2027.
Thymosin alpha-1 played no part in this. The committee reviewed seven substances across two days, and it was not among them (Notice). It does hold orphan drug designation for four rare conditions. That is an incentive to develop a drug, not permission to sell one (Review). Europe granted a similar designation for liver cancer in 2002, and it never became an approval across the EU (Register).
Sport is the one clear-cut piece. The 2026 World Anti-Doping Agency list names thymosin beta-4 and its related forms among banned growth factors, with TB-500 spelled out as the example (List). It is banned at all times, in competition and out of it. That wording was added in 2018 (Summary). Thymosin alpha-1 is not named on the list, which is not the same as cleared. A catch-all section covers substances that no government health authority anywhere has approved for people. Thymalfasin does hold approvals in some countries, so that test is not a simple yes. A tested athlete should ask their own anti-doping body, not a seller.
Frequently Asked Questions
Is thymosin alpha-1 FDA approved?
No. Thymosin alpha-1 is registered in more than 35 countries, mostly for hepatitis B and C. It is not approved for sale in the United States (Review). The FDA has granted it orphan drug designation for four rare conditions, which is a development incentive, not an approval.
Is TB-500 the same as thymosin beta-4?
No. Thymosin beta-4 is a protein of 43 amino acids. TB-500 usually means a seven-amino-acid fragment copied from part of it (Analysis). Confusingly, when three vials labeled with these names were tested, all three held the full protein rather than the fragment (Analysis).
Does TB-500 heal injuries in people?
Nobody knows, because it has not been tested that way. No published human trial has measured injected TB-500 for tendon or ligament repair (Review). Rats given it after tendon surgery did heal better, but that is an early animal study (Study). The related human trials used thymosin beta-4 on the skin or the eye, not the fragment in a syringe.
Is TB-500 legal to buy in 2026?
As of early August 2026 it is not an approved drug in the United States, and pharmacies cannot lawfully compound it (Analysis). An advisory committee recommended adding it to the compounding list in July 2026, but that vote is not binding and changed no law. Rules differ by country, so check where you live.
Will TB-500 show up on a drug test?
Yes, if the test looks for it. The 2026 World Anti-Doping Agency list names thymosin beta-4 and its related forms, TB-500 included, as banned at all times (List). That wording was added in 2018 (Summary). A doping lab set out a way to spot the fragment in blood and urine back in 2012 (Analysis).
Key Takeaways
- Registered abroad is not the same as proven. Thymalfasin is a prescription medicine in more than 35 countries, mainly for hepatitis B and C. That is a legal status, not a level of proof (Review).
- The biggest sepsis trial came back flat. Among 1,106 adults, about 23 in every 100 died on thymosin alpha-1, against 24 in every 100 on a dummy injection (Trial). Pooling 11 trials suggested a benefit, but it vanished in the five stronger studies (Meta-analysis).
- Banned in sport at all times. The 2026 anti-doping list names thymosin beta-4 and its related forms, TB-500 included, among banned growth factors (List).
- The COVID-19 reputation rests on look-backs. The famous 2020 result reviewed 76 patients after the fact. Doctors, not a coin flip, decided who got the drug (Study).
- TB-500 has no published human trial for injuries. The registry holds one TB-500 record, and it labels itself a fictional example (Registry).
- You cannot be sure what is in the vial. Products bought as research chemicals held the wrong molecule, some as little as 5% pure, with arsenic above the injectable limit (Analysis).
Know What You Are Injecting
One of these peptides has a real clinical record, contested and largely disappointing, built by doctors under supervision. The other borrows its name from a relative and arrives in a vial nobody can verify. Neither one belongs in a bathroom cabinet.
If peptides still interest you, the next step is a conversation, not a checkout page. Take four questions to a clinician who knows your history. Where does this come from? What proof of purity is there? What is legal where I live? What does it mean for drug testing if I compete? A clinician who cannot answer all four is a reason to wait.
Researchers are still asking whether thymosin alpha-1 helps particular groups of patients rather than everyone (Meta-analysis). TB-500 may yet get the human trial it has never had. Until then the biology stays interesting and the proof stays thin. There is no good reason to be your own first test subject. The evidence is still building, and it is worth watching.
This article is for educational purposes and is not medical advice. Talk to a qualified clinician before changing your health regimen.
Bio-Hacking.Blog 
Leave a comment